PINCELL
6.5.2020 18:02:10 CEST | Business Wire | Press release
PinCell , a biotechnology company developing novel therapies for rare dermatological diseases, announced today the appointment of Gabriella Camboni, M.D., as Chief Executive Officer of PinCell and Member of the Board of Directors, and Luigi Costa as Chairman of the Board. Paola Pozzi, Partner at Sofinnova Partners, also joins PinCell’s Board following a successful seed financing of €1.65 million led by Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan. The financing was part of a series of investments recently made through The Sofinnova Telethon Fund , the largest fund in Italy dedicated to early-stage biotech startups targeting cures for rare and genetic diseases.
Dr. Camboni is a clinical pharmacologist with 18 years of experience in oncology drug development. She is Chief Executive Officer of BiovelocITA, Italy’s first biotech accelerator, co-founded by Sofinnova Partners in 2015. Dr. Camboni is also co-founder and Chief Operating Officer at Ethical Oncology Science (EOS), an Italian startup dedicated to translational medicine in oncology. Previously, Dr. Camboni co-founded and acted as Head of Development at Novuspharma, a biopharma developing innovative treatments for cancer. Both EOS and Novuspharma are part of Sofinnova Partners’ portfolio alumni.
“I am happy to have the opportunity to help develop a game-changing treatment together with an outstanding scientific team and my long-term associates of Sofinnova Partners,” commented Dr. Camboni.
PinCell also bolstered its Board of Directors with the appointment of Luigi Costa as Chairman of the Board. Mr. Costa has over 25 years of international pharmaceutical and biotech experience. He is an Entrepreneur in Residence at Sofinnova Partners and was the CEO of Nordic Nanovector, a biopharma developing novel targeted therapies for cancer. He also served as Board Member of Oncopeptides AS, a clinical stage biotech company developing a new treatment for Multiple Mieloma. Previously Mr. Costa was Regional Head International at Onyx Pharmaceuticals, acquired by Amgen in 2014, and held several leadership positions with Amgen including Head of International Oncology Franchise, General Manager of Italy and President of France, Amgen’s largest market outside the US. He also held various leadership positions of increasing responsibility with Eli Lilly both in Europe and in the US.
“I am very pleased to have the opportunity to support PinCell in the development of its innovative treatment for a severe autoimmune disease. I am confident that PinCell’s outstanding scientific team, together with my colleagues at Sofinnova Partners, will be able to bring a new therapeutic option to patients," said Mr. Costa.
PinCell’s lead program targets a rare autoimmune bullous disease called Pemphigus, which is characterized by blistering and erosions of the skin and mucous membranes. The condition is chronic, debilitating and potentially life-threatening. PinCell’s unique solution uses an innovative mechanism that inhibits the development of the typical skin blisters, without suppressing the immune system. This is a central factor that makes the treatment less prone to immune-related side effects, enabling patients to have a better quality of life.
Ms. Pozzi commented: “We are pleased to invest in this exceptional team of serial entrepreneurs who have significant clinical expertise in dermatological disorders. They have built strong relationships with US pharma-experienced consultants and international patients’ associations.”
The financing secured last month will advance the company’s development of first-in-class anti-inflammatory therapies for the treatment of rare and severe skin diseases with limited therapeutic options.
Carlo Pincelli, M.D., Professor of Dermatology at the University of Modena and Reggio Emilia and Co-founder of PinCell, said: “We are delighted to have secured financing from Sofinnova Partners, an investor with unparalleled authority and expertise in the biotech domain, as well as the support of experienced biotech executives. Together we are confident we will progress towards clinical studies for the benefit of patients suffering from these debilitating skin conditions.”
About PinCell
PinCell is a biotechnology company targeting a novel pathological pathway to develop first-in-class anti-inflammatory therapies for the treatment of rare, severe skin diseases with high unmet medical need. Based in Milan, Italy, PinCell was founded in October 2008 as an academic spin-off of the University of Modena and Reggio Emilia by the world-class dermatology experts Prof. Carlo Pincelli and Dr. Alessandra Marconi. PinCell received seed funding from Sofinnova Partners.
For more information, please visit: www.pincell.it
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, with offices in London and Milan, the firm brings together a team of 40 professionals from all over Europe, the U.S. and Asia. The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to late-stage/public companies. It has backed nearly 500 companies over more than 48 years, creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management.
For more information, please visit: www.sofinnovapartners.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200506005517/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TetraMem Announces 22nm Multi-Level RRAM Analog In-Memory Computing SoC Milestone16.5.2026 10:43:00 CEST | Press release
TetraMem Inc., a Silicon Valley–based semiconductor company developing analog in-memory computing (IMC) solutions, today announced the successful tape-out, manufacturing, and initial silicon validation of its MLX200 platform, a 22nm multi-level RRAM-based analog IMC system-on-chip (SoC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260516556464/en/ Photograph of the MLX200 chip with a five-cent coin for size reference The achievement marks a significant step toward the commercialization of analog computing architectures based on emerging non-volatile memory technologies, addressing the growing challenges of data movement, power consumption, and thermal constraints in modern AI systems. As AI workloads continue to scale, system performance is increasingly constrained by the cost of moving data between memory and compute units. Analog in-memory computing offers a fundamentally different approach by performing computation dir
STARTEEPO Invest Announces 5% Stake in Xerox Holdings Corporation15.5.2026 18:15:00 CEST | Press release
STARTEEPO Invest (“STARTEEPO”), an alternative investment fund focused on public equity opportunities, today announced that it has acquired a significant ownership position in Xerox Holdings Corporation (“Xerox” or the “Company”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260515594020/en/ As of the date of this release, STARTEEPO and its affiliates beneficially owns 6.6 million shares of Xerox (excluding options), representing approximately 5.05% of the Company’s outstanding common stock. STARTEEPO has filed a Schedule 13D with the U.S. Securities and Exchange Commission (the “SEC”) providing additional details regarding its investment. Investment Perspective STARTEEPO believes that Xerox represents an interesting investment opportunity supported by a combination of balance sheet initiatives, ongoing operational improvements, and its position within a changing and consolidating industry. In STARTEEPO’s view, the Company
NTT DATA Announces Intent to Acquire WinWire to Scale Enterprise AI Adoption and Accelerate Industry Transformation with Microsoft15.5.2026 16:00:00 CEST | Press release
Accelerates AI‑driven transformation through expanded agentic AI and data engineering capabilities that underpin NTT DATA’s AI strategy Adds 1,000 Azure engineers and AI specialists to scale cloud and AI delivery capabilities Advances NTT DATA’s North America leadership position, scaling industry aligned AI led innovation across its cloud services and Microsoft Business Unit Builds on NTT DATA’s position as the fastest-growing Microsoft GSI partner, accelerating co-innovation in enterprise AI NTT DATA, a global leader in AI, digital business and IT services, today announced it has signed a definitive agreement to acquire WinWire,an award-winning Microsoft partner specializing in Agentic AI, AI on Azure, data engineering and cloud-native development as foundational capabilities for enterprise AI. The acquisition strengthens NTT DATA’s position as a trusted partner to help organizations move beyond experimentation to operationalize AI at scale. The acquisition further advances NTT DATA’s
NTT DATA Announces Intent to Acquire WinWire to Scale Enterprise AI Adoption and Accelerate Industry Transformation with Microsoft15.5.2026 16:00:00 CEST | Press release
Accelerates AI‑driven transformation through expanded agentic AI and data engineering capabilities that underpin NTT DATA’s AI strategy Adds 1,000 Azure engineers and AI specialists to scale cloud and AI delivery capabilities Advances NTT DATA’s North America leadership position, scaling industry aligned AI led innovation across its cloud services and Microsoft Business Unit Builds on NTT DATA’s position as the fastest-growing Microsoft GSI partner, accelerating co-innovation in enterprise AI NTT DATA, a global leader in AI, digital business and IT services, today announced it has signed a definitive agreement to acquire WinWire,an award-winning Microsoft partner specializing in Agentic AI, AI on Azure, data engineering and cloud-native development as foundational capabilities for enterprise AI. The acquisition strengthens NTT DATA’s position as a trusted partner to help organizations move beyond experimentation to operationalize AI at scale. The acquisition further advances NTT DATA’s
Experian Expands Agent Trust Partner Ecosystem with Akamai to Advance Trusted AI Driven Commerce15.5.2026 15:00:00 CEST | Press release
Collaboration strengthens secure, scalable agentic commerce and supports emerging Know Your Agent standards Experian today announced that Akamai Technologies has joined its growing partner ecosystem, designed to further advance secure, trusted AI driven commerce through the Experian Agent Trust™ framework, alongside partner Skyfire supporting emerging payment innovation. As AI agents begin to search, decide, and transact autonomously, they introduce a fundamental challenge for businesses: how to trust an action when it is no longer directly initiated by a human. Without a verified connection between humans and AI agents, autonomous commerce introduces new risks in fraud, misrepresentation, and unauthorized transactions. Experian Agent Trust is designed to address this challenge by establishing identity, accountability, and trust in agent driven interactions. “Trust, security, and performance must scale alongside the growing role of AI agents in digital commerce,” said Kathleen Peters,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom